Boehringer sues Mylan over aspirin product
German pharmaceutical company Boehringer Ingelheim has sued generic drug maker Mylan for infringing a patent covering its Aggrenox drug.
Aggrenox, which combines dipyridamole with acetylsalicylic acid (aspirin), is prescribed to reduce the risk of stroke in people who have experienced a mini-stroke or stroke due to a blood clot.
Boehringer has asserted its US patent 6,015,577, which covers pharmaceutical compositions containing dipridamole or mopidamol and acetylsalicylic acid, processes for preparing them and their use in treating blood clot formation.
In the complaint, filed on July 30 at the US District Court for the District of New Jersey, Boehringer said Mylan has sought approval to make a generic version of Aggrenox before the ‘577 patent expires.
Boehringer argued that Mylan did not deny infringement of the patent in its notice letter to the German company, and that the only defences of patent invalidity it asserted were of obviousness and anticipation.
The pharmaceutical company has asked for a declaration that Mylan has infringed the ‘577 patent and a permanent injunction stopping Mylan from making the product.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk